A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study to Investigate the Efficacy (Immunogenicity) and Safety of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Trial Profile

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study to Investigate the Efficacy (Immunogenicity) and Safety of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs GC 3106A (Primary) ; GSK 2321138A
  • Indications Influenza virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors Green Cross
  • Most Recent Events

    • 26 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 25 Feb 2016 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 05 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top